Adding tiragolumab or low-dose ipilimumab to standard liver cancer therapy didn’t improve survival and increased side effects.

Adding tiragolumab to atezolizumab and bevacizumab did not improve progression-free or overall survival in untreated advanced hepatocellular carcinoma, according to a phase 3 trial presented at the 2025 ESMO Congress. The study, involving 669 patients, found no significant benefit in median progression-free survival (8.2 vs. 8.3 months) and immature overall survival data. A separate phase 2 trial also showed that adding low-dose ipilimumab to atezolizumab-bevacizumab did not improve outcomes and increased severe side effects. These results reinforce the current standard of triplets like atezolizumab-bevacizumab, durvalumab-tremelimumab, and nivolumab-ipilimumab, with treatment choices guided by individual patient factors.